ArticlePLoS neglected tropical diseases2016
Association of Fasciola hepatica Infection with Liver Fibrosis, Cirrhosis, and Cancer: A Systematic Review.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 87 citations in OpenAlex.
- Non-viral hepatocellular carcinoma masquerading as a liver abscess: a case report highlighting a diagnostic challenge.International journal of surgery case reports · 2026Article
- Mitochondrial genome analysis supports zoonotic transmission of triclabendazole-resistant human fascioliasis in Peru.One health (Amsterdam, Netherlands) · 2025Article
- Study onPrevalence of Parasitic Infections Among Hepatitis C Virus Patients in Egypt.Archives of Razi Institute · 2025Article
- Hepatic Fascioliasis Complicated by Multisite Venous Thromboembolism: A Rare Association and Implications for Parasite-Associated Coagulopathy.Clinical case reports · 2025Article
- Enolase and 16.5-kDa Tegument-Associated Protein inJournal of extracellular biology · 2025Article
- Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica.Nature communications · 2025Article
- A landscape review with novel criteria to evaluate microbial drivers for cancer: priorities for innovative research targeting excessive cancer mortality in sub-Saharan Africa.Frontiers in cellular and infection microbiology · 2025Review
- Mechanistic insights into liver-fluke-induced bile-duct cancer.Trends in parasitology · 2024Review
- Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.Biomolecules · 2024Review
- New benzimidazole derivative compounds with in vitro fasciolicidal properties.Parasites & vectors · 2024Article
- Optimization and workflow of in vitro culture of adult Fasciola hepatica.Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria · 2024Article
- Isorhamnetin: what is theFrontiers in pharmacology · 2024Review
- An Update on the Pathogenesis of Fascioliasis: What Do We Know?Research and reports in tropical medicine · 2024Review
- Recent advances in computerized imaging and its vital roles in liver disease diagnosis, preoperative planning, and interventional liver surgery: A review.World journal of gastrointestinal surgery · 2023Review
- Epidemiological Investigation of Yak (Animals : an open access journal from MDPI · 2023Article
- Cancerogenic parasites in veterinary medicine: a narrative literature review.Infectious agents and cancer · 2023Review
- Article
- Exploring the role of macrophages in determining the pathogenesis of liver fluke infection.Parasitology · 2022Review
- [Screening and identification of key genes ATP1B3 and ENAH in the progression of hepatocellular carcinoma: based on data mining and clinical validation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Human Fascioliasis (Liver Fluke Disease) in Hawai'i: Case Report and Review of Human Fascioliasis Acquired in the United States.Hawai'i journal of health & social welfare · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFascioliasis has been sporadically associated with chronic liver disease on previous studies. In order to describe the current evidence, we carried out a systematic review to assess the association between fascioliasis with liver fibrosis, cirrhosis and cancer. METHODOLOGY AND PRINCIPAL
findingsA systematic search of electronic databases (PubMed, LILACS, Scopus, Embase, Cochrane, and Scielo) was conducted from June to July 2015 and yielded 1,557 published studies. Among 21 studies that met inclusion and exclusion criteria, 12 studies explored the association of F. hepatica with liver fibrosis, 4 with liver cirrhosis, and 5 with cancer. Globally these studies suggested the ability of F. hepatica to promote liver fibrosis and cirrhosis. The role of F. hepatica in cancer is unknown. Given the heterogeneity of the studies, a meta-analysis could not be performed.
conclusionsFuture high-quality studies are needed to determine the role of F. hepatica on the development of liver fibrosis, liver cirrhosis, and cancer in humans.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.